New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian disease Kumar Jeetendra | June 12, 2021 Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced effective results, dramatically restricting tumor growth and diminishing tumor mass. Designed especially for ovarian cancers that are resistant to conventional therapies, the new radiopharmaceutical could be produced in 25 minutes at reduced cost, which contributes to better efficiency compared with alternative procedures. This …
Small molecule drug can weaken the triggers of neuroinflammation, preclinical review shows Kumar Jeetendra | September 24, 2021 Neuroinflammation may cause worse outcomes in cases of stroke, injuries to the brain or injury, and can increase the severity of neurodegenerative diseases such as ALS, Parkinson’s, or Alzheimer’s. This suggests that reducing neuroinflammation might be an exciting new method to treat neurological disorders and neuropathic pain caused by neuroinflammation. In a preclinical study , …
Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations Kumar Jeetendra | September 25, 2021 Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit …
Nano-bubbles containing ACE2 protein can hinder contamination from wide strains of SARS-CoV-2 Kumar Jeetendra | January 21, 2022 Northwestern Medicine and The University of Texas MD Anderson Cancer Center discovered that natural nano-bubbles containing ACE2 protein (evACE2) were found in the blood of COVID-19 victims. They also discovered that these particles could block infection by broad strains of SARS/CoV-2 virus. Scientists said that the evACE2 acts in the body as a decoy and …
